(Q33381709)

26 July 2017

1 reference

title

Intravenous immunoglobulins: evolution of commercial IVIG preparations (English)

1 reference

26 July 2017

John A Hooper

1

1 reference

26 July 2017

publication date

1 November 2008

1 reference

Immunology and Allergy Clinics of North America

26 July 2017

published in

1 reference

26 July 2017

volume

28

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

765-78, viii

1 reference

Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration

26 July 2017

cites work

1 reference

12 December 2020

Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency

1 reference

12 December 2020

Reduction in risk of hepatitis transmission by heat-treatment of a human Factor VIII concentrate.

1 reference

12 December 2020

Inactivation of the Hutchinson strain of non-A, non-B hepatitis virus by combined use of beta-propiolactone and ultraviolet irradiation

1 reference

12 December 2020

Functional activities of various preparations of human intravenous immunoglobulin against type III group B Streptococcus

1 reference

12 December 2020

Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons

1 reference

12 December 2020

Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma

1 reference

12 December 2020

Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma

1 reference

12 December 2020

The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma

1 reference

12 December 2020

Inactivation of hepatitis C virus in low pH intravenous immunoglobulin

1 reference

12 December 2020

Use of intravenous immune globulin in patients receiving bone marrow transplants

1 reference

12 December 2020

Potential contribution of mild pepsin treatment at pH4 to the viral safety of human immunoglobulin products

1 reference

12 December 2020

Intravenous administration of human gamma-globulin

1 reference

12 December 2020

Inactivation of HTLV-III/LAV during plasma fractionation

1 reference

12 December 2020

Development of an intravenous gamma-globulin with Fc activities. I. Preparation and characterization of S-sulfonated human gamma-globulin

1 reference

12 December 2020

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

1 reference

12 December 2020

Functional capacity of immunoglobulin G preparations and the F(ab')2 split product

1 reference

12 December 2020

The preparation of plasmin treated immune serum globulin for intravenous use

1 reference

12 December 2020

Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma

1 reference

12 December 2020

Blood-borne viral infections.

1 reference

12 December 2020

Provisional Public Health Service inter-agency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome.

1 reference

12 December 2020

A new preparation of modified immune serum globulin (human) suitable for intravenous administration. I. Standardization of the reduction and alkylation reaction

1 reference

12 December 2020

Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids.

1 reference

12 December 2020

Partitioning of TSE infectivity during ethanol fractionation of human plasma

1 reference

12 December 2020

The Ausria test: critical evaluation of sensitivity and specificity

1 reference

12 December 2020

Haemophilus influenzae type b opsonins of intravenous immunoglobulins

1 reference

12 December 2020

Elimination of viruses (human immunodeficiency, hepatitis B, vesicular stomatitis and Sindbis viruses) from an intravenous immunoglobulin preparation

1 reference

12 December 2020

Antibodies Reactive with Human T-Lymphotropic Retroviruses (HTLV-III) in the Serum of Patients with AIDS

1 reference

12 December 2020

Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans

1 reference

12 December 2020

Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process

1 reference

12 December 2020

Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates

1 reference

12 December 2020

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

1 reference

12 December 2020

Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action

1 reference

12 December 2020

Virus removal studies using nanofiltration membranes.

1 reference

12 December 2020

[On new possibilities of intravenous gamma globulin administration.]

1 reference

12 December 2020

1 reference

12 December 2020

Plasma derivatives and viral hepatitis

1 reference

12 December 2020

CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XXXVI. INACTIVATION OF THE VIRUS OF HOMOLOGOUS SERUM HEPATITIS IN SOLUTIONS OF NORMAL HUMAN SERUM ALBUMIN BY MEANS OF HEAT.

1 reference

12 December 2020

Rapid clearance of cytomegalovirus-specific IgG after repeated intravenous infusions of human immunoglobulin into allogeneic bone marrow transplant recipients

1 reference

12 December 2020

Three generations of immunoglobulin G preparations for clinical use.

1 reference

12 December 2020

Non-A, non-B hepatitis from intravenous immunoglobulin

1 reference

12 December 2020

Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates

1 reference

12 December 2020

Undegraded human immunoglobulin for intravenous use

1 reference

12 December 2020

Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration

1 reference

12 December 2020

Elimination of infectious retroviruses during preparation of immunoglobulins

1 reference

12 December 2020

Effect of dry-heating of coagulation factor concentrates at 80 degrees C for 72 hours on transmission of non-A, non-B hepatitis. Study Group of the UK Haemophilia Centre Directors on Surveillance of Virus Transmission by Concentrates

1 reference

12 December 2020

Virus inactivation during production of intravenous immunoglobulin

1 reference

12 December 2020

10.1016/J.IAC.2008.06.002

Identifiers

DOI

1 reference

26 July 2017

1 reference